Research Institute of Tuberculosis, Japan Anti-Tuberculosis Association, Kiyose, Tokyo 204-8533, Japan.
Antimicrob Agents Chemother. 2010 Jun;54(6):2684-6. doi: 10.1128/AAC.01545-09. Epub 2010 Apr 5.
The in vitro activities of DC-159a against seven species of Mycobacterium were compared with moxifloxacin, gatifloxacin, levofloxacin, and rifampin. DC-159a was the most active compound against quinolone-resistant multidrug-resistant M. tuberculosis (MIC(90), 0.5 microg/ml) as well as drug-susceptible isolates (MIC(90), 0.06 microg/ml). The anti-tubercle bacilli activity of DC-159a was 4- to 32-fold more potent than those of currently available quinolones. DC-159a also demonstrated the highest activities against clinically important nontuberculous mycobacteria.
将 DC-159a 与莫西沙星、加替沙星、左氧氟沙星和利福平进行比较，评估其对 7 种分枝杆菌的体外活性。DC-159a 对耐氟喹诺酮类药物的多重耐药结核分枝杆菌（MIC90，0.5μg/ml）以及药敏分离株（MIC90，0.06μg/ml）最为有效。DC-159a 的抗结核分枝杆菌活性比目前可用的氟喹诺酮类药物强 4 至 32 倍。DC-159a 对临床重要的非结核分枝杆菌也具有最高的活性。
